Ultivue – Assay Development & Services
- Assay Design and Development
- Proof-of-Concept (PoC) Design and Execution
- Concordance Studies
- Assay Verification/Validation
- Clinical Trial Support
An end-to-end solution empowers your team to attain quantitative insights in a fraction of the time, without in-house development costs.
| Geographic Coverage | Global |
|---|---|
| Primary Service Focus | mIF Assay Development, Spatial Profiling |
| Typical Adopter | Biopharma/Pharma Focus, Research Focus |
| Regulatory/Accreditation | Research/GLP Standards |
| Turnaround Time | Longer (> 4 Weeks), Standard (1-4 Weeks), Very Rapid (< 3 Days) |
| Sample Types Processed | Physical Samples Only |
| Access to Consultation | Multi-disciplinary Team |
| Common Stains/Assays Offered | Advanced Assays Included |
Be the first to review “Ultivue – Assay Development & Services” Cancel reply
Have you considered:
Compare Solutions
No products to compare
Get Pathology News Delivered to Your Inbox
News
Editor2026-08-14T06:48:56+00:00
Techcyte and elea Bring AI-Native Pathology Reporting into Techcyte FusionⓇ
Editor2026-08-14T06:48:56+00:00August 13, 2026|
Editor2026-08-13T08:46:16+00:00
Pathologic Characterization of Non-Mass Enhancement Lesions of the Breast in MRI-guided Biopsy
Editor2026-08-13T08:46:16+00:00August 13, 2026|
Editor2026-08-14T06:49:00+00:00
OnePath Diagnostic Now Runs on elea’s AI-Native Pathology Operating System
Editor2026-08-14T06:49:00+00:00August 13, 2026|
Editor2026-08-12T08:47:23+00:00
A multisite survey on patient perspectives of breast cancer risk assessment and supplemental breast cancer screening tools
Editor2026-08-12T08:47:23+00:00August 12, 2026|
Editor2026-08-10T07:51:40+00:00
Keeping Digital Pathology Open: The Regulatory Framework Behind Concentriq AP-Dx
Editor2026-08-10T07:51:40+00:00August 12, 2026|
Editor2026-08-11T14:54:03+00:00
Lumea Climbs the 2026 Inc. 5000 Ranking, Reflecting Continued Rapid Growth
Editor2026-08-11T14:54:03+00:00August 11, 2026|
Editor2026-08-11T13:08:19+00:00
Leica Biosystems Enables Faster Cancer Diagnoses Through Multiple Digital Pathology FDA Clearances, Including Industry-First AI-Assisted Quality Control Software
Editor2026-08-11T13:08:19+00:00August 11, 2026|

























Reviews
There are no reviews yet.